Swine Respiratory Diseases Treatment Market by Causative Agent, Treatment, Route of Administration, Distribution Channel, & Region | Forecast to 2022 to 2032
Can Biotechnology Breakthroughs Provide an Impetus to Swine Respiratory Diseases Treatment Options? Read Details in FMI's New Report!
Swine Respiratory Diseases Treatment Market Outlook (2022 to 2032)
[276 Pages Report] The global swine respiratory diseases treatment market size is expected to reach a valuation of US$ 2.0 Billion by the end of 2022, and further expand at a CAGR of 6.3% from 2022 to 2032. The market is likely to reach a valuation of US$ 3.6 Billion by the end of 2032. Mycoplasma under the causative agent segment is leading the swine respiratory diseases treatment market and it held a share of about 35.2% in 2021.
Based on the severity and duration of the observable condition, swine respiratory disorders can be grouped into two main categories: those that affect a significant number of pigs and may be hazardous but only last a short while, and those that affect a large number of pigs for an extended period of time. Costs of diseases in the first category are limited rather than continuing.
Swine influenza, classical swine fever, pneumonic pseudorabies, porcine circovirus-associated illness, and pig reproductive and respiratory syndrome (PRRS) are categorized among them. Although pathogenic viruses may survive in a herd, outbreaks of overt sickness are usually self-limiting. Mycoplasma pneumonia and pleuropneumonia are the most common syndromes in the second category like rhinitis atrophic.
Attributes
Key Statistics
Global Swine Respiratory Diseases Treatment Market Estimated Size (2022E)
US$ 1,978.1 Million
Projected Market Valuation (2032F)
US$ 3,649.5 Million
Value-based CAGR (2022 to 2032)
6.3%
Collective Value Share: Top 5 Countries
61.4%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2012 to 2021 Global Swine Respiratory Diseases Treatment Demand Outlook Compared to 2022 to 2032 Forecast
The global swine respiratory diseases treatment market held approximately 1.9% of the overall veterinary services market, which was worth ~US$ 99.5 Billion in 2021. Sales of swine respiratory disease treatment services expanded at a CAGR of 6.1% from 2012 to 2021.
Demand for swine respiratory disease treatment options is on the rise due to the increasing number of foodborne and zoonotic diseases. According to the most recent annual report on food diseases issued by the European Food Safety Authority (EFSA) and the European Center for Disease Prevention and Control (ECDC) in February 2021, foodborne infections are on the rise compared to the previous year, with pathogenic bacteria such as campylobacter spp. being the most common cause.
Around 5175 food outbreaks were documented, accounting for 49463 clinical cases, 3859 hospital admissions, and 60 deaths (+50% compared to the previous year). Salmonella, norovirus, escherichia coli, yersinia enterocolitica, cryptosporidium parvum, and campylobacter jejuni were the most common etiological agents found, while the most common causes of infection were eggs & egg products, bakery items, hog meat, processed foods, water, crustaceans, and vegetables.
Additionally, the market for swine respiratory diseases treatment is anticipated to grow in terms of research & development (R&D) spending and revenue owing to external partnerships and strategic alliances between industries and academia. For instance, in September 2022, Zoetis acquired NewMetrica, which had developed cutting-edge digital instruments in the form of standardized questionnaires that were intended to evaluate health-related quality of life (HRQL) in nonverbal species, as a strategic addition to their companion animal portfolio. Thus, owing to the aforementioned factors, the global swine respiratory diseases treatment market is expected to grow at a CAGR of 6.3% during the forecast period from 2022 to 2032.
Top Trend Pushing Sales of Swine Respiratory Diseases Treatment Options
Government Investments to Boost Access to Advanced Treatment Will Aid Growth
The market is likely to provide an opportunistic perspective owing to various initiatives by governments in emerging countries. Government bodies are investing significantly in healthcare infrastructure modernization, which is expected to bolster access to advanced healthcare services. This factor is set to fuel demand for upgraded technologies, thereby creating an appealing opportunity in the global swine respiratory diseases treatment market.
In high-income economies like the UK and the USA, there will likely be a greater emphasis on innovation to prevent zoonotic diseases combined with biotechnology breakthroughs, which will create a favorable environment for the development of veterinary therapeutics. These methods include systems biology, synthetic biology, and next-generation sequencing among others. Additionally, maintaining investments in multidisciplinary research may accelerate the time to market for new products and enhance the efficiency of therapy development.
The large market potential for veterinary therapeutics is expected to emerge throughout the forecast period as a result of growing economies in emerging markets like Latin America and Asia Pacific. The potential that these markets present are due to a large number of factors, including the increasing cost of living for the urban middle-class population in these regions, which further surges per-capita meat consumption and fuels the need for more effective livestock farming.
Find your sweet spots for generating winning opportunities in this market.
Which Factors Are Restraining the Demand for Swine Respiratory Diseases Treatment Options?
Stringent regulations put forward by the USA Food & Drug Administration (FDA) to limit the use of antibiotics for farm animals and the rising cost of innovation-dampening Research and Development investments can hamper the market in the forecast period. If antibiotics are administered to livestock that is raised for food such as swine and other animals, they may lose their efficacy in humans. Antibiotic-resistant bacteria known as superbugs are on the rise as a result of the widespread use of antibiotics in both humans and animals.
The cost of drug innovation has been increasing, as compared to earlier years. The trend is similar for animal healthcare. This is primarily attributed to a limited scope of research for newer diseases in livestock animals. Due to this, drug makers are investing more in the development of innovative drugs for diseases, which are already highly mature. This further raises Research and Development spending and dampens return on investment (ROI). These factors cumulatively propose a negative effect on developmental growth in the swine respiratory diseases treatment market.
Country-wise Insights
What Makes the USA a Large Hub for Swine Respiratory Diseases Treatment Producers?
Rising Prevalence of Zoonotic Diseases in the USA to Push Growth by 2032
The USA dominates the North American swine respiratory diseases treatment market and held a total share of about 52.9% in 2021. It is expected to continue to experience the same growth rate throughout the forecast period.
Owing to the increased swine respiratory diseases related deaths, high consumption of animal meats, and growing prevalence of zoonotic diseases, producers or manufacturers operating in the market are presented with new growth opportunities to develop unique preventive measures, which would further boost the market in the USA
What Makes Canada a Highly Lucrative Industry for Swine Respiratory Diseases Treatment?
Surging Need for H1N1 Influenza Treatment in Canada to Drive the Industry Forward
Canada held approximately 47.1% of the share in the North American swine respiratory diseases treatment market in 2021 and it is expected to showcase growth at a lucrative CAGR of 6.7% during the forecast period.
Influenza viruses are frequently found in pigs, who can be infected by humans, birds, or other pigs. Predominant influenza subtypes prevalent in pigs in Canada are H1N1, H1N2, and H3N2. Swine influenza viruses do not generally infect humans; however, these viruses have occasionally infected humans.
Cases mainly emerge because of direct or indirect contact with pigs in numerous settings such as farms or agricultural fairs. The Canadian Food Inspection Agency (CFIA) advises veterinarians and producers to maintain strict biosecurity measures to reduce any hazards to human or animal health.
What is the Outlook of Germany in the Swine Respiratory Diseases Treatment Industry?
Rising Cases of Swine Fever in Pigs to Propel Growth in Germany by 2032
Germany is set to exhibit a CAGR of nearly 5.8% in the Europe swine respiratory diseases treatment market during the forecast period. Germany is becoming increasingly popular when it comes to health and innovation. With the surging prevalence of influenza A (H1), as well as increasing surveillance and management measures of the disease implemented by the World Health Organization (WHO), the demand for swine respiratory disease treatment options will grow at a rapid pace.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which is the Highly Preferred Causative Agent in the Swine Respiratory Diseases Industry?
Mycoplasma-based Swine Diseases to Exhibit High Growth in the Upcoming Decade
Mycoplasma-based causative agents are expected to witness high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 35.2% in 2021. The major pathogen of enzootic pneumonia, a chronic respiratory disease in pigs, is mycoplasma hyopneumoniae. Infections caused by mycoplasma hyopneumoniae are common in practically all swine production locations, which leads to huge economic losses due to increased medicine consumption and lower pig performance.
Which is the Most Common Type of Swine Respiratory Diseases Treatment Worldwide?
Common Swine Diseases Are Expected to Be Treated with Antibiotics
The drugs segment is expected to create high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 63.8% in 2021. Antibiotic use during all stages of growth enhances the efficiency and efficacy of body weight gain, lowers death rates & comorbidities, reduces subclinical disease, and improves pig health.
Which Route of Administration is Gaining Immense Popularity Globally?
Veterans Prefer Oral Route of Administration to Treat Swine Fever Disease
The oral route of administration is expected to exhibit high growth at a CAGR of 6.3% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 86.3% in 2021. The oral route of administration is the most common form of medication administration in farm animals. Medications are mixed with animal feed for ease of ingestion, which would push the segment.
Which is the Most Preferred Distribution Channel across the Globe?
Veterinary Hospitals to Offer Advanced Treatment Options for Swine Bacterial Diseases
Veterinary hospitals held the highest swine respiratory diseases treatment market share of 37.0% in 2021. Pigs are considered to be better medical research subjects than mice as their size, physiology, and genetic makeup are more similar to humans.
Competitive Landscape
With several competitors in the swine respiratory diseases treatment market, the overall industry is highly fragmented. To meet rising consumer demand and expand their customer base, these companies are implementing various methods such as mergers & acquisitions, partnerships & collaborations, and new product launches.
Some of the recent developments in the swine respiratory diseases treatment market are given below:
Merck Animal Health, also known as MSD Animal Health outside of the USA and Canada, declared in March 2022 that AROVYNTM (tulathromycin injection) and NUFLOR-S (florfenicol injectable solution), two broad-spectrum, prescription antibiotics used to treat the primary pathogens linked to swine respiratory disease (SRD), had been approved by the USA Food and Drug Administration (FDA).
In September 2021, Invetx and Boehringer Ingelheim announced a collaboration to discover, develop, and commercialize innovative veterinary medications.
Scope of the Swine Respiratory Diseases Treatment Market Report
Attribute
Details
Estimated Market Size (2022)
US$ 1,978.1 Million
Projected Market Valuation (2032)
US$ 3,649.5 Million
Value-based CAGR (2022 to 2032)
6.3%
Forecast Period
2012 to 2021
Historical Data Available for
2022 to 2032
Market Analysis
Value (US$ Million)
Key Regions Covered
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered
USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, North Africa, and South Africa
Key Market Segments Covered
Causative Agent, Treatment, Route of Administration, Distribution Channel, and Region
Key Companies Profiled
Zoetis
Bayer AG
Boehringer Ingelheim GmbH
Elanco Animal Health (Sub. Eli Lilly)
Virbac
Norbrook
Ceva Santé Animale
Intervet Inc., (Sub. Merck & Co. Inc.)
Vetoquinol SA
Bimeda Inc.
Kyoritsu Seiyaku Corporation
HIPRA
Agrilabs, Inc.
Ashish LifeSciences Ltd.
Cipla Pharmaceuticals.
Thermo Fisher Scientific Inc.
Huvepharma
Report Coverage
Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Key Segments Covered in Swine Respiratory Diseases Treatment Market Report
By Causative Agent:
Virus
Mycoplasma
Bacteria
Others
By Treatment:
Drugs
Antibiotics
Others
Vaccines
By Route of Administration:
Oral
Parenteral
By Distribution Channel:
Veterinary Hospitals
Veterinary Clinics
Pharmacies
Others
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)
Frequently Asked Questions
How much was the swine respiratory diseases treatment market worth in 2021?
The global swine respiratory diseases treatment market was worth US$ 1,852.0 Million in 2021 and is set to expand 1.8x over the next ten years.
What is the sales forecast for the swine respiratory diseases treatment market through 2032?
The swine respiratory diseases treatment market is expected to reach US$ 3,649.5 Million by the end of 2032, with sales revenue set to register a 6.3% CAGR.
What are the key trends shaping the swine respiratory diseases treatment market?
Emergence of biologics & specialty care, growing awareness & affordability of therapeutics for livestock, and shifting distribution of drugs from traditional channels are some of the key trends in the swine respiratory diseases treatment market.
Which are the top five countries driving the swine respiratory disease treatment market?
The USA, Canada, China, the Philippines, and South Korea are expected to drive demand in the swine respiratory diseases treatment market.
What is the North America swine respiratory disease treatment market outlook?
North America is one of the key regions, with the USA accounting for about 52.9% of the region’s swine respiratory diseases treatment market in the year 2021.
At what percentage is the swine respiratory disease treatment market expected to grow in Japan?
The swine respiratory disease treatment market in Japan is expected to register growth at a CAGR of 5.2% over the next ten years.
At what rate is the swine respiratory disease treatment market expected to grow in Germany?
The swine respiratory disease treatment market in Germany is expected to register growth at a CAGR of 5.8% over the next ten years.
Which countries are the key producers of swine respiratory disease treatment products?
China, the USA, and the Philippines are the key producers of swine respiratory diseases treatment
Who are the key players in the swine respiratory diseases treatment market?
Zoetis, Bayer AG, Boehringer Ingelheim GmbH, Elanco Animal Health (Sub. Eli Lilly), Virbac, Norbrook, Ceva Santé Animale, Intervet Inc. (Sub. Merck & Co. Inc.), Vetoquinol SA, Bimeda, Inc., Kyoritsu Seiyaku Corporation, HIPRA, Agrilabs, Inc., Ashish LifeSciences Ltd., Cipla Pharmaceuticals., Thermo Fisher Scientific Inc., and Huvepharma, are some of the key players in the swine respiratory diseases treatment market.
At what rate is the swine respiratory disease treatment market expected to grow in South Korea?
The global swine respiratory disease treatment market in South Korea is expected to register growth at a CAGR of 6.1% over the next ten years.
Table of Content
1. Executive Summary | Swine Respiratory Diseases Treatment Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology
4.2. Key Promotional Strategies - by Manufacturers
4.3. Regulatory Scenario
4.4. Reimbursement Scenario
4.5. Porter’s Analysis
4.6. PESTLE Analysis
4.7. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Veterinary Services Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. New Product Launches
5.2.2. Rise in Consumption of Pork
5.2.3. Increasing Requirement of Quality of Life in Animal Healthcare
5.2.4. Increasing Research and Development Activities
5.2.5. Adoption of Veterinary Vaccination
5.2.6. Introduction of Novel and Advanced Technologies
5.2.7. Government Investments in Veterinary Diseases
5.2.8. Increasing Prevalence of Porcine Reproductive and Respiratory Syndrome
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Causative Agent
6.1.2. By Treatment
6.1.3. By Route of Administration
6.1.4. By Distribution Channel
6.1.5. By Country
6.2. 2021 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021
7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Causative Agent
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis and Forecast By Causative Agent, 2012 to 2021
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Causative Agent, 2022 to 2032
8.3.1. Virus
8.3.2. Mycoplasma
8.3.3. Bacteria
8.3.4. Others
8.4. Market Attractiveness Analysis By Causative Agent
9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Treatment
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Treatment, 2012 to 2021
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Treatment, 2022 to 2032
9.3.1. Drugs
9.3.1.1. Antibiotics
9.3.1.2. Others
9.3.2. Vaccines
9.4. Market Attractiveness Analysis By Treatment
10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Route of Administration
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis, By Route of Administration, 2012 to 2021
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032
10.3.1. Oral
10.3.2. Parenteral
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2012 to 2021
11.3. Current and Future Market Size (US$ Million) Analysis Forecast By Distribution Channel, 2022 to 2032
11.3.1. Veterinary Hospitals
11.3.2. Veterinary Clinics
11.3.3. Pharmacies
11.3.4. Others
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021
12.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
13.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
13.4.1. By Country
13.4.1.1. United States of America
13.4.1.2. Canada
13.4.2. By Causative Agent
13.4.3. By Treatment
13.4.4. By Route of Administration
13.4.5. By Distribution Channel
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Causative Agent
13.5.3. By Treatment
13.5.4. By Route of Administration
13.5.5. By Distribution Channel
13.6. Market Trends
13.7. Key Market Participants - Intensity Mapping
13.8. Drivers and Restraints - Impact Analysis
13.9. Country-Level Analysis & Forecast
13.9.1. USA Market Analysis
13.9.1.1. .Introduction
13.9.1.2. Market Analysis and Forecast by Market Taxonomy
13.9.1.2.1. By Causative Agent
13.9.1.2.2. By Treatment
13.9.1.2.3. By Route of Administration
13.9.1.2.4. By Distribution Channel
13.9.2. Canada Market Analysis
13.9.2.1. Introduction
13.9.2.2. Market Analysis and Forecast by Market Taxonomy
13.9.2.2.1. By Causative Agent
13.9.2.2.2. By Treatment
13.9.2.2.3. By Route of Administration
13.9.2.2.4. By Distribution Channel
14. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2012 to 2021
14.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032
14.4.1. By Country
14.4.1.1. Mexico
14.4.1.2. Brazil
14.4.1.3. Argentina
14.4.1.4. Rest of Latin America
14.4.2. By Causative Agent
14.4.3. By Treatment
14.4.4. By Route of Administration
14.4.5. By Distribution Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Causative Agent
14.5.3. By Treatment
14.5.4. By Route of Administration
14.5.5. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
14.9. Country-Level Analysis & Forecast
14.9.1. Mexico Market Analysis
14.9.1.1. Introduction
14.9.1.2. Market Analysis and Forecast by Market Taxonomy
14.9.1.2.1. By Causative Agent
14.9.1.2.2. By Treatment
14.9.1.2.3. By Route of Administration
14.9.1.2.4. By Distribution Channel
14.9.2. Brazil Market Analysis
14.9.2.1. Introduction
14.9.2.2. Market Analysis and Forecast by Market Taxonomy
14.9.2.2.1. By Causative Agent
14.9.2.2.2. By Treatment
14.9.2.2.3. By Route of Administration
14.9.2.2.4. By Distribution Channel
14.9.3. Argentina Market Analysis
14.9.3.1. Introduction
14.9.3.2. Market Analysis and Forecast by Market Taxonomy
14.9.3.2.1. By Causative Agent
14.9.3.2.2. By Treatment
14.9.3.2.3. By Route of Administration
14.9.3.2.4. By Distribution Channel
15. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2012 to 2021
15.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. Italy
15.4.1.3. France
15.4.1.4. United Kingdom
15.4.1.5. Spain
15.4.1.6. BENELUX
15.4.1.7. Russia
15.4.1.8. Nordic Countries
15.4.1.9. Rest of Europe
15.4.2. By Causative Agent
15.4.3. By Treatment
15.4.4. By Route of Administration
15.4.5. By Distribution Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Causative Agent
15.5.3. By Treatment
15.5.4. By Route of Administration
15.5.5. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
15.9. Country-Level Analysis & Forecast
15.9.1. Germany Market Analysis
15.9.1.1. Introduction
15.9.1.2. Market Analysis and Forecast by Market Taxonomy
15.9.1.2.1. By Causative Agent
15.9.1.2.2. By Treatment
15.9.1.2.3. By Route of Administration
15.9.1.2.4. By Distribution Channel
15.9.2. Italy Market Analysis
15.9.2.1. Introduction
15.9.2.2. Market Analysis and Forecast by Market Taxonomy
15.9.2.2.1. By Causative Agent
15.9.2.2.2. By Treatment
15.9.2.2.3. By Route of Administration
15.9.2.2.4. By Distribution Channel
15.9.3. France Market Analysis
15.9.3.1. Introduction
15.9.3.2. Market Analysis and Forecast by Market Taxonomy
15.9.3.2.1. By Causative Agent
15.9.3.2.2. By Treatment
15.9.3.2.3. By Route of Administration
15.9.3.2.4. By Distribution Channel
15.9.4. UK Market Analysis
15.9.4.1. Introduction
15.9.4.2. Market Analysis and Forecast by Market Taxonomy
15.9.4.2.1. By Causative Agent
15.9.4.2.2. By Treatment
15.9.4.2.3. By Route of Administration
15.9.4.2.4. By Distribution Channel
15.9.5. Spain Market Analysis
15.9.5.1. Introduction
15.9.5.2. Market Analysis and Forecast by Market Taxonomy
15.9.5.2.1. By Causative Agent
15.9.5.2.2. By Treatment
15.9.5.2.3. By Route of Administration
15.9.5.2.4. By Distribution Channel
15.9.6. BENELUX Market Analysis
15.9.6.1. Introduction
15.9.6.2. Market Analysis and Forecast by Market Taxonomy
15.9.6.2.1. By Causative Agent
15.9.6.2.2. By Treatment
15.9.6.2.3. By Route of Administration
15.9.6.2.4. By Distribution Channel
15.9.7. Russia Market Analysis
15.9.7.1. Introduction
15.9.7.2. Market Analysis and Forecast by Market Taxonomy
15.9.7.2.1. By Causative Agent
15.9.7.2.2. By Treatment
15.9.7.2.3. By Route of Administration
15.9.7.2.4. By Distribution Channel
15.9.8. Nordic Countries Market Analysis
15.9.8.1. Introduction
15.9.8.2. Market Analysis and Forecast by Market Taxonomy
15.9.8.2.1. By Causative Agent
15.9.8.2.2. By Treatment
15.9.8.2.3. By Route of Administration
15.9.8.2.4. By Distribution Channel
16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
16.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
16.4.1. By Country
16.4.1.1. China
16.4.1.2. Japan
16.4.1.3. South Korea
16.4.2. By Causative Agent
16.4.3. By Treatment
16.4.4. By Route of Administration
16.4.5. By Distribution Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Causative Agent
16.5.3. By Treatment
16.5.4. By Route of Administration
16.5.5. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
16.9. Country-Level Analysis & Forecast
16.9.1. China Market Analysis
16.9.1.1. Introduction
16.9.1.2. Market Analysis and Forecast by Market Taxonomy
16.9.1.2.1. By Causative Agent
16.9.1.2.2. By Treatment
16.9.1.2.3. By Route of Administration
16.9.1.2.4. By Distribution Channel
16.9.2. Japan Market Analysis
16.9.2.1. Introduction
16.9.2.2. Market Analysis and Forecast by Market Taxonomy
16.9.2.2.1. By Causative Agent
16.9.2.2.2. By Treatment
16.9.2.2.3. By Route of Administration
16.9.2.2.4. By Distribution Channel
16.9.3. South Korea Market Analysis
16.9.3.1. Introduction
16.9.3.2. Market Analysis and Forecast by Market Taxonomy
16.9.3.2.1. By Causative Agent
16.9.3.2.2. By Treatment
16.9.3.2.3. By Route of Administration
16.9.3.2.4. By Distribution Channel
17. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
17.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
17.4.1. By Country
17.4.1.1. India
17.4.1.2. Indonesia
17.4.1.3. Malaysia
17.4.1.4. Thailand
17.4.1.5. Rest of South Asia
17.4.2. By Causative Agent
17.4.3. By Treatment
17.4.4. By Route of Administration
17.4.5. By Distribution Channel
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Causative Agent
17.5.3. By Treatment
17.5.4. By Route of Administration
17.5.5. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
17.9. Country-Level Analysis & Forecast
17.9.1. India Market Analysis
17.9.1.1. Introduction
17.9.1.2. Market Analysis and Forecast by Market Taxonomy
17.9.1.2.1. By Causative Agent
17.9.1.2.2. By Treatment
17.9.1.2.3. By Route of Administration
17.9.1.2.4. By Distribution Channel
17.9.2. Indonesia Market Analysis
17.9.2.1. Introduction
17.9.2.2. Market Analysis and Forecast by Market Taxonomy
17.9.2.2.1. By Causative Agent
17.9.2.2.2. By Treatment
17.9.2.2.3. By Route of Administration
17.9.2.2.4. By Distribution Channel
17.9.3. Malaysia Market Analysis
17.9.3.1. Introduction
17.9.3.2. Market Analysis and Forecast by Market Taxonomy
17.9.3.2.1. By Causative Agent
17.9.3.2.2. By Treatment
17.9.3.2.3. By Route of Administration
17.9.3.2.4. By Distribution Channel
17.9.4. Thailand Market Analysis
17.9.4.1. Introduction
17.9.4.2. Market Analysis and Forecast by Market Taxonomy
17.9.4.2.1. By Causative Agent
17.9.4.2.2. By Treatment
17.9.4.2.3. By Route of Administration
17.9.4.2.4. By Distribution Channel
17.9.5. Rest of South Asia Market Analysis
17.9.5.1. Introduction
17.9.5.2. Market Analysis and Forecast by Market Taxonomy
17.9.5.2.1. By Causative Agent
17.9.5.2.2. By Treatment
17.9.5.2.3. By Route of Administration
17.9.5.2.4. By Distribution Channel
18. Oceania Market 2012 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
18.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
18.4.1. By Country
18.4.1.1. Australia
18.4.1.2. New Zealand
18.4.2. By Causative Agent
18.4.3. By Treatment
18.4.4. By Route of Administration
18.4.5. By Distribution Channel
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Causative Agent
18.5.3. By Treatment
18.5.4. By Route of Administration
18.5.5. By Distribution Channel
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country-Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Causative Agent
18.8.1.2.2. By Treatment
18.8.1.2.3. By Route of Administration
18.8.1.2.4. By Distribution Channel
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Causative Agent
18.8.2.2.2. By Treatment
18.8.2.2.3. By Route of Administration
18.8.2.2.4. By Distribution Channel
19. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032
19.1. Introduction
19.2. Pricing Analysis
19.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
19.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
19.4.1. By Country
19.4.1.1. GCC Countries
19.4.1.2. Turkey
19.4.1.3. South Africa
19.4.1.4. North Africa
19.4.1.5. Rest of Middle East and Africa
19.4.2. By Causative Agent
19.4.3. By Treatment
19.4.4. By Route of Administration
19.4.5. By Distribution Channel
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Causative Agent
19.5.3. By Treatment
19.5.4. By Route of Administration
19.5.5. By Distribution Channel
19.6. Market Trends
19.7. Key Market Participants - Intensity Mapping
19.8. Drivers and Restraints - Impact Analysis
19.9. Country-Level Analysis & Forecast
19.9.1. GCC Countries Market Analysis
19.9.1.1. Introduction
19.9.1.2. Market Analysis and Forecast by Market Taxonomy
19.9.1.2.1. By Causative Agent
19.9.1.2.2. By Treatment
19.9.1.2.3. By Route of Administration
19.9.1.2.4. By Distribution Channel
19.9.2. Turkey Market Analysis
19.9.2.1. Introduction
19.9.2.2. Market Analysis and Forecast by Market Taxonomy
19.9.2.2.1. By Causative Agent
19.9.2.2.2. By Treatment
19.9.2.2.3. By Route of Administration
19.9.2.2.4. By Distribution Channel
19.9.3. South Africa Market Analysis
19.9.3.1. Introduction
19.9.3.2. Market Analysis and Forecast by Market Taxonomy
19.9.3.2.1. By Causative Agent
19.9.3.2.2. By Treatment
19.9.3.2.3. By Route of Administration
19.9.3.2.4. By Distribution Channel
19.9.4. North Africa Market Analysis
19.9.4.1. Introduction
19.9.4.2. Market Analysis and Forecast by Market Taxonomy
19.9.4.2.1. By Causative Agent
19.9.4.2.2. By Treatment
19.9.4.2.3. By Route of Administration
19.9.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Concentration
20.3. Market Share Analysis of Top Players
20.4. Market Presence Analysis
20.4.1. By Regional footprint of Players
20.4.2. Product foot print by Players
20.4.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Zoetis
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Key Financials
21.3.1.6. SWOT Analysis
21.3.1.7. Strategy Overview
21.3.2. Bayer AG
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Key Financials
21.3.2.6. SWOT Analysis
21.3.2.7. Strategy Overview
21.3.3. Boehringer Ingelheim GmbH
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Key Financials
21.3.3.6. SWOT Analysis
21.3.3.7. Strategy Overview
21.3.4. Elanco Animal Health (Sub. Eli Lilly)
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Key Financials
21.3.4.6. SWOT Analysis
21.3.4.7. Strategy Overview
21.3.5. Virbac
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Key Financials
21.3.5.6. SWOT Analysis
21.3.5.7. Strategy Overview
21.3.6. Norbrook
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Key Financials
21.3.6.6. SWOT Analysis
21.3.6.7. Strategy Overview
21.3.7. Ceva Santé Animale
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Key Financials
21.3.7.6. SWOT Analysis
21.3.7.7. Strategy Overview
21.3.8. Intervet Inc., (Sub. Merck & Co. Inc.)
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Key Financials
21.3.8.6. SWOT Analysis
21.3.8.7. Strategy Overview
21.3.9. Vetoquinol SA
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Key Financials
21.3.9.6. SWOT Analysis
21.3.9.7. Strategy Overview
21.3.10. Bimeda Inc.,
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
21.3.10.4. Sales Footprint
21.3.10.5. Key Financials
21.3.10.6. SWOT Analysis
21.3.10.7. Strategy Overview
21.3.11. Kyoritsu Seiyaku Corporation
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Profitability by Market Segments (Product/Channel/Region)
21.3.11.4. Sales Footprint
21.3.11.5. Key Financials
21.3.11.6. SWOT Analysis
21.3.11.7. Strategy Overview
21.3.12. HIPRA
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Profitability by Market Segments (Product/Channel/Region)
21.3.12.4. Sales Footprint
21.3.12.5. Key Financials
21.3.12.6. SWOT Analysis
21.3.12.7. Strategy Overview
21.3.13. Agrilabs, Inc.,
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Profitability by Market Segments (Product/Channel/Region)
21.3.13.4. Sales Footprint
21.3.13.5. Key Financials
21.3.13.6. SWOT Analysis
21.3.13.7. Strategy Overview
21.3.14. Ashish Lifesciences Ltd.,
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Profitability by Market Segments (Product/Channel/Region)
21.3.14.4. Sales Footprint
21.3.14.5. Key Financials
21.3.14.6. SWOT Analysis
21.3.14.7. Strategy Overview
21.3.15. Cipla Pharmaceuticals.
21.3.15.1. Overview
21.3.15.2. Product Portfolio
21.3.15.3. Profitability by Market Segments (Product/Channel/Region)
21.3.15.4. Sales Footprint
21.3.15.5. Key Financials
21.3.15.6. SWOT Analysis
21.3.15.7. Strategy Overview
21.3.16. Thermo Fisher Scientific Inc.,
21.3.16.1. Overview
21.3.16.2. Product Portfolio
21.3.16.3. Profitability by Market Segments (Product/Channel/Region)
21.3.16.4. Sales Footprint
21.3.16.5. Key Financials
21.3.16.6. SWOT Analysis
21.3.16.7. Strategy Overview
21.3.17. Huvepharma.
21.3.17.1. Overview
21.3.17.2. Product Portfolio
21.3.17.3. Profitability by Market Segments (Product/Channel/Region)
21.3.17.4. Sales Footprint
21.3.17.5. Key Financials
21.3.17.6. SWOT Analysis
21.3.17.7. Strategy Overview
22. Assumptions and Acronyms Used23. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Size (US$ Million) Analysis and Forecast 2022 to 2032, by Causative Agent
Table 02: Global Market Size (US$ Million) Analysis and Forecast 2022 to 2032, by Treatment
Table 03: Global Market Size (US$ Million) Analysis and Forecast 2022 to 2032, by Route of Administration
Table 04: Global Market Value (US$ Million) Analysis and Forecast 2022 to 2032, by Distribution Channel
Table 05: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 06: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 07: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 08: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 09: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 10: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 11: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 12: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 13: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 14: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 15: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 16: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 17: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 18: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 19: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 20: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 21: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 22: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 23: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 24: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 25: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 26: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 27: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 28: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 29: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 30: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 31: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 32: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 33: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 34: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 35: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 36: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 37: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 38: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 39: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Market Value Analysis (US$ Million), 2012 to 2021
Figure 02: Global Market Value Forecast (US$ Million), 2022 to 2032
Figure 03: Global Market Absolute $ Opportunity, 2022 to 2032
Figure 04: Global Market Share Analysis (%), by Causative Agent, 2022 to 2032
Figure 05: Global Market Y-o-Y Analysis (%), by Causative Agent, 2022 to 2032
Figure 06: Global Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 07: Global Market Share Analysis (%), by Treatment, 2022 to 2032
Figure 08: Global Market Y-o-Y Analysis (%), by Treatment, 2022 to 2032
Figure 09: Global Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 10: Global Market Share Analysis (%), by Route of Administration, 2022 to 2032
Figure 11: Global Market Y-o-Y Analysis (%), by Route of Administration, 2022 to 2032
Figure 12: Global Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 13: Global Market Share Analysis (%), by Distribution Channel, 2022 to 2032
Figure 14: Global Market Y-o-Y Analysis (%), by Distribution Channel, 2022 to 2032
Figure 15: Global Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 16: North America Market Value Share by Causative Agent 2022 (E)
Figure 17: North America Market Value Share by Treatment 2022 (E)
Figure 18: North America Market Value Share by Route of Administration 2022 (E)
Figure 19: North America Market Value Share by Distribution Channel 2022 (E)
Figure 20: North America Market Value Share by Country 2022 (E)
Figure 21: North America Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 22: North America Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 23: North America Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 24: North America Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 25: North America Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 26: North America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 27: North America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 28: USA Market Value Proportion Analysis, 2021
Figure 29: USA Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 30: USA Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 31: USA Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 32: USA Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 33: Canada Market Value Proportion Analysis, 2021
Figure 34: Canada Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 35: Canada Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 36: Canada Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 37: Canada Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 38: Latin America Market Value Share by Causative Agent 2022 (E)
Figure 39: Latin America Market Value Share by Treatment 2022 (E)
Figure 40: Latin America Market Value Share by Route of Administration 2022 (E)
Figure 41: Latin America Market Value Share by Distribution Channel 2022 (E)
Figure 42: Latin America Market Value Share by Country 2022 (E)
Figure 43: Latin America Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 44: Latin America Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 45: Latin America Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 46: Latin America Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 47: Latin America Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 49: Latin America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 50: Brazil Market Value Proportion Analysis, 2021
Figure 51: Brazil Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 52: Brazil Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 53: Brazil Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 54: Brazil Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 55: Mexico Market Value Proportion Analysis, 2021
Figure 56: Mexico Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 57: Mexico Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 58: Mexico Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 59: Mexico Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 60: Argentina Market Value Proportion Analysis, 2021
Figure 61: Argentina Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 62: Argentina Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 63: Argentina Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 64: Argentina Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 65: Europe Market Value Share by Causative Agent 2022 (E)
Figure 66: Europe Market Value Share by Treatment 2022 (E)
Figure 67: Europe Market Value Share by Route of Administration 2022 (E)
Figure 68: Europe Market Value Share by Distribution Channel 2022 (E)
Figure 69: Europe Market Value Share by Country 2022 (E)
Figure 70: Europe Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 71: Europe Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 72: Europe Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 73: Europe Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 74: Europe Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 75: Europe Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 76: Europe Market Attractiveness Analysis by Country, 2022 to 2032
Figure 77: Italy Market Value Proportion Analysis, 2021
Figure 78: Italy Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 79: Italy Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 80: Italy Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 81: Italy Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 82: Germany Market Value Proportion Analysis, 2021
Figure 83: Germany Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 84: Germany Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 85: Germany Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 86: Germany Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 87: U.K. Market Value Proportion Analysis, 2021
Figure 88: U.K. Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 89: U.K. Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 90: U.K. Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 91: U.K. Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 92: France Market Value Proportion Analysis, 2021
Figure 93: France Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 94: France Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 95: France Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 96: France Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 97: Spain Market Value Proportion Analysis, 2021
Figure 98: Spain Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 99: Spain Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 100: Spain Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 101: Spain Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 102: BENELUX Market Value Proportion Analysis, 2021
Figure 103: BENELUX Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 104: BENELUX Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 105: BENELUX Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 106: BENELUX Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 107: Nordic Countries Market Value Proportion Analysis, 2021
Figure 108: Nordic Countries Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 109: Nordic Countries Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 110: Nordic Countries Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 111: Nordic Countries Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 112: Russia Market Value Proportion Analysis, 2021
Figure 113: Russia Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 114: Russia Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 115: Russia Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 116: Russia Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 117: South Asia Market Value Share by Causative Agent 2022 (E)
Figure 118: South Asia Market Value Share by Treatment 2022 (E)
Figure 119: South Asia Market Value Share by Route of Administration 2022 (E)
Figure 120: South Asia Market Value Share by Distribution Channel 2022 (E)
Figure 121: South Asia Market Value Share by Country 2022 (E)
Figure 122: South Asia Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 123: South Asia Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 124: South Asia Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 125: South Asia Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 126: South Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 127: South Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 128: South Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 129: India Market Value Proportion Analysis, 2021
Figure 130: India Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 131: India Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 132: India Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 133: India Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 134: Thailand Market Value Proportion Analysis, 2021
Figure 135: Thailand Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 136: Thailand Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 137: Thailand Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 138: Thailand Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 139: Indonesia Market Value Proportion Analysis, 2021
Figure 140: Indonesia Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 141: Indonesia Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 142: Indonesia Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 143: Indonesia Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 144: Malaysia Market Value Proportion Analysis, 2021
Figure 145: Malaysia Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 146: Malaysia Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 147: Malaysia Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 148: Malaysia Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 149: East Asia Market Value Share by Causative Agent 2022 (E)
Figure 150: East Asia Market Value Share by Treatment 2022 (E)
Figure 151: East Asia Market Value Share by Route of Administration 2022 (E)
Figure 152: East Asia Market Value Share by Distribution Channel 2022 (E)
Figure 153: East Asia Market Value Share by Country 2022 (E)
Figure 154: East Asia Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 155: East Asia Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 156: East Asia Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 157: East Asia Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 158: East Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 159: East Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 160: East Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 161: China Market Value Proportion Analysis, 2021
Figure 162: China Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 163: China Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 164: China Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 165: China Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 166: Japan Market Value Proportion Analysis, 2021
Figure 167: Japan Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 168: Japan Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 169: Japan Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 170: Japan Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 171: South Korea Market Value Proportion Analysis, 2021
Figure 172: South Korea Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 173: South Korea Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 174: South Korea Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 175: South Korea Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 176: Oceania Market Value Share by Causative Agent 2022 (E)
Figure 177: Oceania Market Value Share by Treatment 2022 (E)
Figure 178: Oceania Market Value Share by Route of Administration 2022 (E)
Figure 179: Oceania Market Value Share by Distribution Channel 2022 (E)
Figure 180: Oceania Market Value Share by Country 2022 (E)
Figure 181: Oceania Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 182: Oceania Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 183: Oceania Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 184: Oceania Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 185: Oceania Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 186: Oceania Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 187: Oceania Market Attractiveness Analysis by Country, 2022 to 2032
Figure 188: Australia Market Value Proportion Analysis, 2021
Figure 189: Australia Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 190: Australia Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 191: Australia Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 192: Australia Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 193: New Zealand Market Value Proportion Analysis, 2021
Figure 194: New Zealand Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 195: New Zealand Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 196: New Zealand Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 197: New Zealand Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 198: Middle East & Africa Market Value Share by Causative Agent 2022 (E)
Figure 199: Middle East & Africa Market Value Share by Treatment 2022 (E)
Figure 200: Middle East & Africa Market Value Share by Route of Administration 2022 (E)
Figure 201: Middle East & Africa Market Value Share by Distribution Channel 2022 (E)
Figure 202: Middle East & Africa Market Value Share by Country 2022 (E)
Figure 203: Middle East & Africa Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 204: Middle East & Africa Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 205: Middle East & Africa Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 206: Middle East & Africa Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 207: Middle East & Africa Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 208: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 209: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032
Figure 210: GCC Countries Market Value Proportion Analysis, 2021
Figure 211: GCC Countries Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 212: GCC Countries Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 213: GCC Countries Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 214: GCC Countries Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 215: South Africa Market Value Proportion Analysis, 2021
Figure 216: South Africa Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 217: South Africa Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 218: South Africa Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 219: South Africa Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 220: North Africa Market Value Proportion Analysis, 2021
Figure 221: North Africa Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 222: North Africa Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 223: North Africa Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 224: North Africa Market Share Analysis (%), by Distribution Channel, 2021 to 2032
